InnocsAI Deal History & Licensing Activity
InnocsAI is a biotech. Over the past three years, InnocsAI has been involved in 2 licensing and acquisition transactions, with a primary focus on CAR-T (4 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
CAR-T
Focus Area
Other
InnocsAI Recent Deal Activity
Licensing, acquisition, and partnership transactions involving InnocsAI in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| InnocsAI CAR-T platform | Liminatus | CAR-T | Unknown | acquisition | May 22, 2026 |
| Liminatus Pharma CAR-T program | Liminatus Pharma | CAR-T | Unknown | acquisition | May 21, 2026 |
InnocsAI Pipeline Focus
Therapeutic areas and modalities where InnocsAI is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
InnocsAI Strategic Signals
Key indicators of InnocsAI's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches InnocsAI's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
CAR-T Benchmarks
Upfront, milestone, and royalty benchmarks for car-t deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About InnocsAI Licensing & Deal Activity
InnocsAI is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, InnocsAI ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for InnocsAI include Other (4 deals and trials). In terms of modality, InnocsAI has shown particular interest in car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for InnocsAI and 850+ other biopharma companies. Use our Solidus to benchmark your asset against InnocsAI's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.